# US 2010/0062988 A1 · Chewable sustained release formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062988 A1
- Document ID: US20100062988A1
- Status: Published application
- Kind: A1
- Application number: 12/554,361
- Filed: 2009-09-04
- Published: 2010-03-11
- Earliest claimed: 2008-09-04
- Assignees: Farnam Companies, Inc.
- Inventors: Andrew Xian Chen; Patricia D. Kigin; Hai Liang Chen; Jun Fan
- Web page: https://patentgrep.com/patent/US20100062988A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/1664: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/1617)}
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Sustained release compositions in tablet or multiparticulate forms comprising (a) an active ingredient, (b) a primary sustain release agent, (c) a wax-like agent, and (d) a bulking or spheronizing agent are provided. The compositions are chewable and/or taste masked. Oral dosage forms comprising such compositions and methods for preparing and using such compositions and dosage forms are also provided.

## Claims

### Claim 1

A composition, comprising:
(a) from about 1% to about 80% by weight of the active ingredient;
(b) from about 1% to about 20% by weight of zein from an aqueous dispersion of zein;
(c) from about 1% to about 70% by weight of a wax-like agent; and
(d) from about 10% to about 50% by weight of microcrystalline cellulose, pregelatinized starch, or a mixture of microcrystalline cellulose and pregelatinized starch,
wherein (i) the composition is in the form of multiparticulates or tablets, (ii) the composition has an in vitro dissolution rate of the active ingredient measured by standard USP basket method of at most about 90% of the active ingredient released after 2 hours, and (iii) the in vitro dissolution rate of the active ingredient does not require the presence of a sustained release barrier coating on the tablets or multiparticulates.

### Claim 2 (depends on 1)

The composition of claim 1, wherein when the tablets are broken into 4 pieces, the composition maintains an in vitro dissolution rate of the active ingredient measured by standard USP basket method of at most about 90% of the active ingredient released after 2 hours.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition has an in vitro dissolution rate of the active ingredient measured by standard USP basket method of:
about 10% to about 60% of the active ingredient released after 4 hours;
about 25% to about 75% of the active ingredient released after 8 hours; and
about 30% to about 90% of the active ingredient released after 12 hours.

### Claim 4 (depends on 3)

The composition of claim 3, wherein when the tablets or multiparticulates are broken into 4 pieces, the composition maintains an in vitro dissolution rate of the active ingredient measured by standard USP basket method of:
about 10% to about 60% of the active ingredient released after 4 hours;
about 25% to about 75% of the active ingredient released after 8 hours; and
about 30% to about 90% of the active ingredient released after 12 hours.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is in the form of multiparticulates.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is in the form of tablets.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the wax-like agent is hydrogenated vegetable oil or carnauba wax.

### Claim 8 (depends on 1)

The composition of claim 1, comprising:
(a) from about 3% to about 25% by weight of the active ingredient;
(b) from about 1% to about 15% by weight of zein from an aqueous dispersion of zein;
(c) from about 5% to about 55% by weight of the wax-like agent; and
(d) from about 15% to about 45% by weight of microcrystalline cellulose, pregelatinized starch, or a mixture of microcrystalline cellulose and pregelatinized starch.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the active ingredient is a drug with a half-life less than 12 hours.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the active ingredient is phenylpropanolamine hydrochloride.

### Claim 11 (depends on 10)

The composition of claim 10, comprising:
(a) from about 0.5% to about 20% by weight of phenylpropanolamine hydrochloride;
(b) from about 0.5% to about 10% by weight of zein from an aqueous dispersion of zein;
(c) from about 20% to about 80% by weight of hydrogenated vegetable oil;
(d) from about 10% to about 40% by weight of microcrystalline cellulose; and
(e) from about 5% to about 25% by weight of pregelatinized starch.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the active ingredient comprises glucosamine HCl.

### Claim 13 (depends on 12)

The composition of claim 12, comprising:
(a) from about 25% to about 75% by weight of glucosamine HCl,
(b) from about 1% to about 15% by weight of zein from an aqueous dispersion of zein,
(c) from about 15% to about 35% by weight of hydrogenated vegetable oil,
(d) from about 5% to about 20% by weight of microcrystalline cellulose, and
(e) from about 5% to about 10% by weight of pregelatinized starch.

### Claim 14 (depends on 12)

The composition of claim 12, further comprising chondroitin, calcium ascorbate, manganese sulfate, or a mixture thereof.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the active ingredient comprises multi-vitamins and minerals.

### Claim 16 (depends on 15)

The composition of claim 15, comprising:
(a) from about 50% to about 80% by weight of multi-vitamins and minerals,
(b) from about 1% to about 10% by weight of zein from an aqueous dispersion of zein,
(c) from about 1% to about 15% by weight of hydrogenated vegetable oil or carnauba wax, and
(d) from about 5% to about 25% by weight of microcrystalline cellulose.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the active ingredient is tramadol HCl.

### Claim 18 (depends on 17)

The composition of claim 17, comprising:
(a) from about 5% to about 30% by weight of tramadol HCl,
(b) from about 1% to about 30% by weight of zein from an aqueous dispersion of zein,
(c) from about 5% to about 50% by weight of hydrogenated vegetable oil or carnauba wax, and
(d) from about 15% to about 60% by weight of microcrystalline cellulose, pregelatinized starch, or a mixture of microcrystalline cellulose and pregelatinized starch.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the tablets or multiparticulates are coated.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the tablets or multiparticulates are coated with a coating composition that comprises hydrogenated vegetable oil or carnauba wax.

### Claim 21 (depends on 1)

The composition of claim 1, wherein at most about 5% of the active ingredient is released during the first 1 to 5 minutes measured by standard USP basket method.

### Claim 22 (depends on 1)

The composition of claim 1, further comprising one or more inactive ingredients.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the inactive ingredient is a binder, antioxidant, colorant, flavor or lubricant.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the one or more inactive ingredients are present at the total concentration from about 0.01% to about 5.0% by weight.

### Claim 25 (depends on 1)

A dosage form comprising the composition of any claim 1.

### Claim 26 (depends on 1)

A method for preparing a composition according to claim 1, comprising:
(a) mixing the active ingredient with zein from an aqueous dispersion of zein to form a core,
(b) mixing the core of step (a) with the wax-like agent, microcrystalline cellulose, optionally pregelatinized starch, and a liquid,
(c) granulating or extruding the mixture of step (b) to obtain granules or extrudates;
(d) drying the granules or extrudates,
(e) heating the dry granules or extrudates of step (d) to a temperature exceeding the melting point of the wax-like agent, and
(f) sizing the granules of step (e) or fragmenting the extrudates of step (e) to form non-spherical pellets.

### Claim 27 (depends on 1)

A method for preparing a composition according to claim 1, comprising:
(a) mixing the active ingredient with zein from an aqueous dispersion of zein to form a core,
(b) mixing the core of step (a) with the wax-like agent, microcrystalline cellulose, optionally pregelatinized starch, and a liquid,
(c) extruding the mixture of step (b) to obtain extrudates;
(d) spherionizing the extrudates to form spherical pellets,
(e) drying the spherical pellets, and
(f) heating the spherical pellets of step (e) to a temperature exceeding the melting point of the wax-like agent.

### Claim 28 (depends on 26)

The method of claim 26, further comprising coating the granulates, non-spherical pellets or spherical pellets with a coating composition that comprises a wax-like agent.

### Claim 29 (depends on 26)

The method of claim 26, further comprising:
(g) mixing the granulates, non-spherical pellets or spherical pellets with one or more inactive ingredients, and
(h) compressing the mixture of step (g) into tablets.

### Claim 30 (depends on 29)

The method of claim 29, further comprising coating the tablets with a coating composition that comprises a wax-like agent.

### Claim 31 (depends on 10)

A method for treating incontinence or congestion or suppressing appetite in an animal, comprising administering orally to an animal patient in need thereof a composition of claim 10 that comprises an effective amount of phenylpropanolamine hydrochloride.

### Claim 32 (depends on 17)

A method for reducing pain, comprising administering orally to a patient in need thereof a composition of claim 17, wherein the composition comprises an effective amount of tramadol or a pharmaceutically acceptable salt.

### Claim 33 (depends on 13)

A method for treating or preventing a chronic disease or a dietary deficiency, comprising administering orally to a patient in need thereof a composition of claim 13, wherein the composition comprises an effective amount of glucosamine hydrochloride, chondroitin sulfate, vitamins, minerals, or a mixture thereof.
